A Study of KC1036 in Adolescents With Advanced Ewing Sarcoma
A Phase II Study to Evaluate the Safety and Efficacy of KC1036 in Adolescents Aged 12 and Above With Advanced Ewing Sarcoma
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Xin Ni
- Phone Number: 010-88324973
- Email: nixin@bch.com.cn
Study Contact Backup
- Name: Huanmin Wang
- Phone Number: 010-88324973
- Email: wanghuanmin@bch.com.cn
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100045
- Recruiting
- Beijing Children's Hospital Affiliated to Capital Medical University
-
Contact:
- Huanming Wang, Ph.D
- Phone Number: 010-88324973
- Email: wanghuanmin@bch.com.cn
-
Principal Investigator:
- Xin Ni, Ph.D
-
Principal Investigator:
- Huanming Wang, Ph.D
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age between 12 and less than 18 years;
- Diagnosed with Ewing sarcoma confirmed by histopathological examination;
- Patients with locally advanced or metastatic Ewing sarcoma that is unresectable or has failed standard treatment, and for whom no other treatment options are available as assessed by the investigator;
- Body weight of ≥30 kg;
- Karnofsky performance status (≥16 years) or Lansky performance status (<16 years) score of ≥60%;
- Patients with at least one measurable lesions according to RECIST v1.1 (Response Evaluation Criteria in Solid Tumors);
- Expected survival of more than 12 weeks;
- Sufficient organ and bone marrow function;
- Female patients who have started menstruating must have a negative pregnancy test;
- The patient and their legal guardians understand and are willing to participate in the trial, and have signed the informed consent form.
Exclusion Criteria:
- Patients with primary central nervous system tumors;
- Presence of central nervous system metastases as diagnosed by imaging;
- History of or concurrent other malignancies within the past 5 years;
- Gastrointestinal abnormalities;
- Cardiovascular or cerebrovascular abnormalities;
- Patients who have previously received VEGFR-TKI small molecule treatment;
- Currently participating in another therapeutic clinical trial; received any anticancer treatment within 2 weeks or 5 half-lives (whichever is longer) before the start of the study treatment; received whole-brain radiation therapy within 14 days before the start of the study treatment; received stereotactic radiosurgery within 7 days before the start of the study treatment; or received herbal or traditional Chinese medicine for anticancer purposes within 2 weeks before the study treatment;
- Underwent major surgery within 2 months before enrollment or have not fully recovered, or plan to undergo surgery during the current study period;
- Persistent toxicity from previous anticancer treatment that has not improved to ≤ Grade 1 (according to CTCAE v5.0), excluding alopecia;
- Unhealed skin wounds, surgical sites, traumatic sites, severe mucosal ulcers, or fractures;
- Uncontrolled significant pleural effusion, ascites, or pericardial effusion;
- Active bacterial, viral, or fungal infections; unexplained fever >38.5°C within 2 weeks before enrollment;
- Hepatitis B surface antigen (HBsAg) positive with HBV-DNA ≥500 IU/mL or 2500 copies/mL; Hepatitis C virus (HCV) antibody positive with HCV RNA ≥200 IU/mL or positive test results; HIV-positive individuals;
- Presence of psychiatric or neurological disorders; or cognitive impairment;
- Fertile patients (e.g., females who have started menstruating or males who have started ejaculating) who do not agree to use contraception (e.g., birth control pills or condoms) during the study and for 6 months after the study ends;
- Patients with insufficient compliance as evaluated by investigator;
- The investigator believes that it is not suitable to patient in this clinical trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: KC1036
oral administration QD
|
For patients weighing between 30 kg and less than 50 kg, administer 40 mg QD of KC1036.
For patients weighing between 50 kg and less than 70 kg, administer 50 mg QD of KC1036.
For patients weighing 70 kg or more, administer 60 mg QD of KC1036.
4 weeks as a cycle.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adverse events (AEs)
Time Frame: approximately 3 years
|
Incidence of treatment-related AEs
|
approximately 3 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Objective Response Rate (ORR)
Time Frame: approximately 3 years
|
Overall response rate (ORR) was defined as the percentage of participants with a best overall complete response (CR) or partial response (PR) per RECIST 1.1.
|
approximately 3 years
|
|
Progression-free survival (PFS)
Time Frame: approximately 3 years
|
Progression-free survival (PFS) was defined as the time from the start date of study drug to the date of the first radiologically documented progressive disease (PD) per RECIST 1.1 or death due to any cause.
|
approximately 3 years
|
|
Disease Control Rate (DCR)
Time Frame: approximately 3 years
|
Disease Control Rate (DCR) was defined as the percentage of participants with a best overall complete response (CR), partial response (PR), or stable disease (SD) per RECIST 1.1.
|
approximately 3 years
|
|
Duration of Response (DOR)
Time Frame: approximately 3 years
|
Duration of response (DOR) was defined as the time from first documented response (partial response (PR) or complete response (CR)) to the date of first documented disease progression (PD) or death due to any cause, among patients with a confirmed PR or CR per RECIST 1.1.
|
approximately 3 years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Huanmin Wang, Beijing Children's Hospital Affiliated to Capital Medical University
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- KC1036-PED-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.